Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.

Date publication

juin 2021

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Uzzan M, Bresteau C, Laharie D, Stefanescu C, Bellanger C, Carbonnel F, Serrero M, Viennot S, Nachury M, Amiot A, Altwegg R, Picon L, Nahon S, Vuitton L, Ah Soune P, Kirchgesner J, Peyrin-Biroulet L, Bouhnik Y,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34151448

Résumé

Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In patients hospitalised for severe flare, who previously experienced multiple drug failures, including steroids and anti-TNF agents, new quick-acting medical options are needed. Tofacitinib is effective in refractory UC and has a rapid onset of action.

Référence

Aliment Pharmacol Ther. 2021 Jun 20;: